Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
2097125-54-5
Molecular formula
C6472H10004N1712O2024S42
Molecular weight
145500 g/mol
Drug class
Activin A-neutralising human monoclonal antibodyactivin A/ALK2 pathway inhibitor
Mechanism of action
Binds activin A and prevents activation of the abnormal ACVR1/ALK2 signalling pathway implicated in fibrodysplasia ossificans progressiva (FOP), reducing formation of heterotopic bone and disease flare-ups.
Indications / reported uses
Reduction of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP) under the US FDA PASATRU indication (approved 19 August 2026)
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Garetosmab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Garetosmab Permitted Daily Exposure (PDE) report (the Garetosmab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Garetosmab Occupational Exposure Limit (OEL) report (the Garetosmab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.